Nomegestrol acetate/17beta-estradiol does not negatively alter the vascular resistance of clitoral arteries: a prospective, exploratory study.


Journal

International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 06 03 2019
accepted: 14 05 2019
revised: 18 04 2019
pubmed: 3 7 2019
medline: 1 12 2020
entrez: 3 7 2019
Statut: ppublish

Résumé

The effect of nomegestrol acetate/estradiol (NOMAC/E2) on clitoral and uterine vascularization has never been evaluated. We aimed to investigate, in women consulting for contraceptive needs, the possible changes in clitoral and uterine arteries hemodynamic parameters after 6 months treatment with NOMAC/E2 as compared with other hormonal contraceptives (HCs). In this observational, prospective pilot study, ten women were enrolled. Color Doppler ultrasound was performed on the clitoral and uterine arteries at baseline and after 6 months treatment with NOMAC/E2 (n = 5) or other HCs (n = 5). NOMAC/E2 did not exert any significant effect on clitoral vascular resistance expressed by the pulsatility index (PI); conversely, treatment with other HCs significantly increased this parameter (p = 0.04). The change in clitoral PI between the two groups retained a statistically significant difference even after adjusting for age. In the NOMAC/E2 group, at follow-up, uterine artery PI and acceleration were significantly reduced (p = 0.04), whereas no significant differences were observed in the HCs group; however, the change in uterine artery parameters did not differ significantly between the two groups. NOMAC/E2, differently from other COCs, does not negatively alter the vascular resistance of clitoral arteries and appears as a good contraceptive choice to protect both cardiovascular and sexual health.

Identifiants

pubmed: 31263248
doi: 10.1038/s41443-019-0162-7
pii: 10.1038/s41443-019-0162-7
doi:

Substances chimiques

Contraceptives, Oral, Hormonal 0
Norpregnadienes 0
Estradiol 4TI98Z838E
nomegestrol acetate 83J78V5W05
Megestrol EA6LD1M70M

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-247

Références

United Nations Department of Economic and Social Affairs Population Division. World Contraceptive Use 2007. http://www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2017 .
Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 mg and 35 mg estrogen preparations. Contraception. 1999;60:321–9.
pubmed: 10715366 doi: 10.1016/S0010-7824(99)00109-2 pmcid: 10715366
Chasan-Taber L, Stampfer M. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 1998;128:467–77.
pubmed: 9499331 doi: 10.7326/0003-4819-128-6-199803150-00008 pmcid: 9499331
Coenen CMH, Thomas CMG, Borm GF, Hollanders JMG, Rollands R. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53:171–6.
pubmed: 8689882 doi: 10.1016/0010-7824(96)00006-6 pmcid: 8689882
Ågren UM, Anttila M, Mäenpää-Liukko K, Rantala ML, Rautiainen H, Sommer WF, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care. 2011;16:458–67.
pubmed: 21942708 pmcid: 3233273 doi: 10.3109/13625187.2011.614363
Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med. 2014;11:462–70.
pubmed: 24286545 doi: 10.1111/jsm.12409 pmcid: 24286545
Zethraeus N, Dreber A, Ranehill E, Blomberg L, Labrie F, von Schoultz B, et al. Combined oral contraceptives and sexual function in women-a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2016;101:4046–53.
pubmed: 27525531 doi: 10.1210/jc.2016-2032 pmcid: 27525531
Casey PM, MacLaughlin KL, Faubion SS. Impact of contraception on female sexual function. J Women’s Health (Larchmt). 2017;26:207–13.
doi: 10.1089/jwh.2015.5703
Rowen TS. Treating sexual side effects from oral contraceptive pills. J Women’s Health (Larchmt). 2017;26:711.
doi: 10.1089/jwh.2017.6369
Khalifé S, Binik YM, Cohen DR, Amsel R. Evaluation of clitoral blood flow by color Doppler ultrasonography. J Sex Marital Ther. 2000;26:187–9.
pubmed: 10782450 doi: 10.1080/009262300278588 pmcid: 10782450
Maseroli E, Fanni E, Cipriani S, Scavello I, Pampaloni F, Battaglia C, et al. Cardiometabolic risk and female sexuality: focus on clitoral vascular resistance. J Sex Med. 2016;13:1651–61.
doi: 10.1016/j.jsxm.2016.09.009
Battaglia C, Battaglia B, Mancini F, Busacchi P, Paganotto MC, Morotti E, et al. Sexual behavior and oral contraception: a pilot study. J Sex Med. 2012;9:550–7.
pubmed: 22188640 doi: 10.1111/j.1743-6109.2011.02597.x pmcid: 22188640
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
doi: 10.1176/appi.books.9780890425596
Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.
pubmed: 10782451 doi: 10.1080/009262300278597 pmcid: 10782451
Filocamo MF, Serati M, Li Marzi V, Costantini E, Milanesi M, Pietropaolo A, et al. The Female Sexual Function Index (FSFI): linguistic validation of the Italian version. J Sex Med. 2014;11:447–53.
pubmed: 24224761 doi: 10.1111/jsm.12389 pmcid: 24224761
Derogatis L, Clayton A, Lewis-D’Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008;5:357–64.
pubmed: 18042215 doi: 10.1111/j.1743-6109.2007.00672.x pmcid: 18042215
Crown S, Crisp AH. A short clinical diagnostic self-rating scale for psychoneurotic patients. The Middlesex Hospital Questionnaire (M.H.Q.). Br J Psychiatry. 1966;112:917–23.
pubmed: 5970912 doi: 10.1192/bjp.112.490.917 pmcid: 5970912
Alderman KJ, Mackay CJ, Lucas EG, Spry WB, Bell B. Factor analysis and reliability studies of the Crown-Crisp Experiential Index (CCEI). Br J Med Psychol. 1983;56:329–45.
pubmed: 6661403 doi: 10.1111/j.2044-8341.1983.tb01565.x pmcid: 6661403
Adali E, Kolusari A, Adali F, Yildizhan R, Kurdoglu M, Sahin HG. Doppler analysis of uterine perfusion and ovarian stromal blood flow in polycystic ovary syndrome. Int J Gynaecol Obstet 2009;105:154–7.
pubmed: 19232596 doi: 10.1016/j.ijgo.2008.12.023 pmcid: 19232596
Gosling RG, King DH. Arterial assessment by Doppler-shift ultrasound. Proc R Soc Med. 1974;67:447–9.
pubmed: 4850636 pmcid: 1645777
Grunewald C, Kublickas M, Nisell H, Nylund L, Westgren M. The interpretation of uterine artery pulsatility index in normal and hypertensive pregnancy. Ultrasound Obstet Gynecol. 1994;4:476–9.
pubmed: 12797128 doi: 10.1046/j.1469-0705.1994.04060476.x
Maseroli E, Scavello I, Vignozzi L. Cardiometabolic Risk and Female Sexuality-Part II. understanding (and overcoming) gender differences: the key role of an adequate methodological approach. Sex Med Rev. 2018;6:525–34.
pubmed: 29661689 pmcid: 29661689 doi: 10.1016/j.sxmr.2018.03.004
Mercier J, Tang A, Morin M, Khalifé S, Lemieux MC, Reichetzer B, et al. Test–retest reliability of clitoral blood flow measurements using color Doppler ultrasonography at rest and after a pelvic floor contraction task in healthy adult women. Neurourol Urodyn. 2018;37:2249–56.
pubmed: 29953674 doi: 10.1002/nau.23582 pmcid: 29953674
Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: a review. J Sex Med. 2012;9:2213–23.
pubmed: 22788250 doi: 10.1111/j.1743-6109.2012.02848.x pmcid: 22788250
Nappi RE, Mancini M, Veneroni F, Colpi GM, Ferdeghini F, Polatti F. Clitoral artery blood flow in healthy young women: preliminary report on menstrual cycle and hormonal contraception. J Sex Marital Ther. 2002;28(Suppl 1):187–93.
pubmed: 11898702 doi: 10.1080/00926230252851311 pmcid: 11898702
Wallwiener CW, Wallwiener LM, Seeger H, Schönfisch B, Mueck AO, Bitzer J, et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Arch Gynecol Obstet. 2015;292:883–90.
pubmed: 25905601 doi: 10.1007/s00404-015-3726-x pmcid: 25905601
Pastor Z, Holla K, Chmel R. The influence of combined oral contraceptives on female sexual desire: a systematic review. Eur J Contracept Reprod Health Care. 2013;18:27–43.
pubmed: 23320933 doi: 10.3109/13625187.2012.728643 pmcid: 23320933
van Lunsen RH1, Laan E. Sex, hormones and the brain. Eur J Contracept Reprod Health Care. 1997;2:247–51.
pubmed: 9678081 doi: 10.3109/13625189709165302 pmcid: 9678081
Greenstein A, Ben-Aroya Z, Fass O, Militscher I, Roslik Y, Chen J, et al. Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. J Sex Med. 2007;4:1679–83.
pubmed: 17970976 doi: 10.1111/j.1743-6109.2007.00621.x pmcid: 17970976
Traish AM, Vignozzi L, Simon JA, Goldstein I, Kim NN. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;6:558–71.
pubmed: 29631981 doi: 10.1016/j.sxmr.2018.03.005 pmcid: 29631981
Greco T, Graham CA, Bancroft J, Tanner A, Doll HA. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception. 2007;76:8–17.
pubmed: 17586130 doi: 10.1016/j.contraception.2007.04.002 pmcid: 17586130
Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12:169–78.
pubmed: 16291771 doi: 10.1093/humupd/dmi046 pmcid: 16291771
Battaglia C, Morotti E, Persico N, Battaglia B, Busacchi P, Casadio P, et al. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. J Sex Med. 2014;11:471–80.
doi: 10.1111/jsm.12392
Park K, Goldstein I, Andry C, Siroky MB, Krane RJ, Azadzoi KM. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. Int J Impot Res. 1997;9:27–37.
pubmed: 9138056 doi: 10.1038/sj.ijir.3900258 pmcid: 9138056
Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res. 2005;17:224–6.
pubmed: 15716979 doi: 10.1038/sj.ijir.3901310 pmcid: 15716979
Alvisi S, Baldassarre M, Lambertini M, Martelli V, Berra M, Moscatiello S, et al. Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. J Sex Med. 2014;11:2020–8.
pubmed: 24848980 doi: 10.1111/jsm.12585 pmcid: 24848980
Martelli V, Valisella S, Moscatiello S, Matteucci C, Lantadilla C, Costantino A, et al. Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med. 2012;9:434–41.
pubmed: 22023878 doi: 10.1111/j.1743-6109.2011.02517.x pmcid: 22023878
Otunctemur A, Dursun M, Ozbek E, Sahin S, Besiroglu H, Koklu I, et al. Effect of metabolic syndrome on sexual function in pre- and postmenopausal women. J Sex Marital Ther. 2015;41:440–9.
pubmed: 24824329 doi: 10.1080/0092623X.2014.918068 pmcid: 24824329
Basdevant A, Pelissier C, Conard J, Degrelle H, Guyene TT, Thomas JL. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception. 1991;44:599–605.
pubmed: 1773617 doi: 10.1016/0010-7824(91)90080-Y pmcid: 1773617
Akintomide H, Panicker S. Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability. Open Access J Contracept. 2015;6:77–86.
pubmed: 29386925 pmcid: 5683186 doi: 10.2147/OAJC.S61942
Espinoza J, Romero R, Mee Kim Y, Kusanovic JP, Hassan S, Erez O, et al. Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med. 2006;34:447–58.
pubmed: 17140293 pmcid: 7062302 doi: 10.1515/JPM.2006.089
Poon LC, Volpe N, Muto B, Yu CK, Syngelaki A, Nicolaides KH. Second-trimester uterine artery Doppler in the prediction of stillbirths. Fetal Diagn Ther. 2013;33:28–35.
pubmed: 22947667 doi: 10.1159/000342109
Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178:701–11.
pubmed: 18332385 pmcid: 2263112 doi: 10.1503/cmaj.070430
McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156:918–30.
pubmed: 19061708 doi: 10.1016/j.ahj.2008.06.042
Alsnes IV, Janszky I, Forman MR, Vatten LJ, Økland I. A population-based study of associations between preeclampsia and later cardiovascular risk factors. Am J Obstet Gynecol. 2014;211:657.e1–7.
doi: 10.1016/j.ajog.2014.06.026
Li J, Wang B, Cai A, Yuan Q, Ding H, Zhao D. Carotid arterial wall stiffness correlates positively with impedance of the umbilical and uterine arteries in women with preeclampsia. J Clin Ultrasound. 2019;47:27–35.
pubmed: 30318601 doi: 10.1002/jcu.22648 pmcid: 30318601
Markovitz AR, Stuart JJ, Horn J, Williams PL, Rimm EB, Missmer SA, et al. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. J Lipid Res. 2018;59:2403–12.
Bluestein D1, Niu L, Schoephoerster RT, Dewanjee MK. Fluid mechanics of arterial stenosis: relationship to the development of mural thrombus. Ann Biomed Eng. 1997;25:344–56.
pubmed: 9084839 doi: 10.1007/BF02648048 pmcid: 9084839

Auteurs

Irene Scavello (I)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Andrology, Women's Endocrinology and Gender Inconguence Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Elisa Maseroli (E)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Andrology, Women's Endocrinology and Gender Inconguence Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Vincenza Di Stasi (V)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Andrology, Women's Endocrinology and Gender Inconguence Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Sarah Cipriani (S)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Andrology, Women's Endocrinology and Gender Inconguence Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Nunzia Verde (N)

Medicine and Surgery, Section of Endocrinology, Federico II, University of Naples, Naples, Italy.

Angela Magini (A)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Andrology, Women's Endocrinology and Gender Inconguence Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

Mario Maggi (M)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Endocrinology Unit, Medical-Geriatric Department, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Istituto Nazionale Biostrutture e Biosistemi, Rome, Italy.

Linda Vignozzi (L)

Department of Experimental, Clinical, and Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy. linda.vignozzi@unifi.it.
Andrology, Women's Endocrinology and Gender Inconguence Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. linda.vignozzi@unifi.it.
Istituto Nazionale Biostrutture e Biosistemi, Rome, Italy. linda.vignozzi@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH